Rein Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Rein Therapeutics, Inc.

Rein Therapeutics, Inc. (NASDAQ: RNTX) is a U.S.-listed biopharmaceutical company headquartered in Austin, Texas, focused on orphan pulmonary and fibrotic diseases. The company was previously known as Aileron Therapeutics, Inc. and rebranded to Rein Therapeutics in January 2025, with its common stock beginning to trade under the RNTX symbol on the NASDAQ. For investors, Rein should be viewed as a clinical-stage biotech with a concentrated asset base and a valuation that is primarily driven by clinical milestones, regulatory progress, and financing execution rather than product revenue. Rein’s business model centers on developing first-in-class medicines for significant unmet medical needs in pulmonary fibrosis and related indications. Its lead program is LTI-03, an inhaled therapy being developed for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. In March 2026, the company announced that it had dosed the first patient in its Phase 2 RENEW trial, following recent FDA clearance to resume the U.S. program. Rein describes LTI-03 as a multi-pathway, caveolin-1-related peptide intended to regulate fibrosis pathways and help preserve lung function. The company’s second key asset is LTI-01, being advanced for loculated pleural effusion (LPE), another orphan pulmonary indication with meaningful unmet need. From a competitive standpoint, Rein operates in a crowded but scientifically attractive biotech niche, where success depends on differentiated efficacy, tolerability, and the ability to generate clean clinical data. The company’s strategy is to focus on serious diseases with limited approved therapies, which can create meaningful value if the clinical profile is compelling. Rein also aims to enhance development efficiency through partnerships; for example, it has collaborated with Qureight to integrate a deep-learning imaging platform into the Phase 2 IPF study, reflecting an effort to improve biomarker and imaging analysis. Recent developments have been material. In 2025, Rein secured regulatory permissions in the U.K. and Europe for Phase 2 development of LTI-03, later received FDA clearance to resume the U.S. trial, and published additional translational data supporting the program. In January 2026, it received European Medicines Agency orphan drug designation for LTI-03. In April 2026, the company announced pricing of a $50 million underwritten public offering, underscoring that continued capital access remains important to fund its clinical pipeline. Overall, Rein Therapeutics is an emerging NASDAQ-listed U.S. biotech whose investment case is tied to high-risk, high-reward pipeline execution in orphan pulmonary disease.